Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer

• Sponsor: Case Comprehensive Cancer Center (Other)
• Overall Status: Terminated
• CT.gov ID: NCT00899132
• Collaborator: National Cancer Institute (NCI) (NIH)
• Enrollment: 180
• Location: 1
• Duration (Months): 67
• Patients Per Site Per Month: 2.7

Study Details

Study Description

Brief Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is evaluating a tumor marker for testicular cancer, skin cancer, small intestine cancer, and pancreatic cancer.

Condition or Disease	Intervention/Treatment	Phase
Non-melanomatous Skin Cancer; Pancreatic Cancer; Small Intestine Cancer; Testicular Germ Cell Tumor	Genetic: in situ hybridization; Genetic: protein expression analysis; Other: immunologic technique

Detailed Description

OBJECTIVES:

• To identify TAB3 transcript/protein as a molecular marker of cancer, specifically testicular, skin, small intestine, and pancreatic cancer.

• To characterize TAB3 and its signaling networks that are involved in tumorigenesis.

OUTLINE: Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.

Study Design

• Study Type: Observational
• Actual Enrollment: 180 participants
• Observational Model: Case-Only
• Time Perspective: Cross-Sectional
• Official Title: The Role of TAB3 Protein in Tumorigenesis
• Study Start Date: Feb 1, 2007
• Actual Primary Completion Date: Sep 1, 2012
• Actual Study Completion Date: Sep 1, 2012

Outcome Measures

Primary Outcome Measures

1. Identification of TAB3 transcript/protein as a molecular marker of cancer [end of study]

2. Characterization of TAB3 and its signaling networks that are involved in tumorigenesis [end of study]

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

DISEASE CHARACTERISTICS:

• Paraffin tissue blocks from surgical pathology cancer cases, specifically testicular, skin, small intestine, and pancreatic cancer, available

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• Not specified

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center	Cleveland	Ohio	United States	44106-5065

Sponsors and Collaborators

• Case Comprehensive Cancer Center
• National Cancer Institute (NCI)

Investigators

• Study Chair: Ge Jin, PhD, Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Case Comprehensive Cancer Center
• ClinicalTrials.gov Identifier: NCT00899132
• Other Study ID Numbers: CASE5Y06; P30CA043703; CASE5Y06; CASE-5Y06-CC191
• First Posted: May 12, 2009
• Last Update Posted: Sep 29, 2015
• Last Verified: Sep 1, 2015

• Keywords provided by Case Comprehensive Cancer Center: skin cancer; small intestine cancer; pancreatic cancer; malignant testicular germ cell tumor; testicular teratoma
• Additional relevant MeSH terms: Pancreatic Neoplasms; Neoplasms, Germ Cell and Embryonal; Skin Neoplasms; Intestinal Neoplasms

Study Results

No Results Posted as of Sep 29, 2015